2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3159 HLA and immune-regulatory remodeling in GPI-deficient hematopoiesis in PNH

Kartik Lakhotiya, MS, Naomi Kawashima2, Karol K Gostomczyk3, Felipe de Almeida Sartori4, Atsushi Marumo, MD5, Mark David Orland, MD, PhD6, Serhan Unlu, MD7, Carmelo Gurnari, MD,PhD8, Charlotte Zurowski9, Carlos Bravo-Perez, MD10, Jackson Hensley, N/A11, Varun K. Venkatesh, N/A12, Christopher Haddad, BS13, Aashray Mandala, BS14, Ajitesh Reddy Busireddy, N/A15, Vibha Balasubramaniam16, Nandini Rajaram Siva, MD17, Luca Guarnera, MD18, Arda Durmaz, PhD19, Ana Plesca, MD20, Akram Abushamma, MD21, Maxwell Hou, N/A22, Matteo D'Addona, MD23, Babal Kant Jha, PhD24, Jaroslaw P. Maciejewski, MD, PhD, FACP25
1 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States, Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States, University of Rome Tor Vergata, Roma, Italy
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States, Hospital Universitario Morales Meseguer, University of Murcia, Murcia, Spain
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States
12 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States
13 Cleveland Clinic Foundation, Cleveland, Ohio, United States
14 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
15 Cleveland Clinic Foundation, Cleveland, Ohio, United States
16 Cleveland Clinic Foundation, Cleveland, Ohio, United States
17 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States
18 Cleveland Clinic Foundation, Cleveland, Ohio, United States, University of Rome Tor Vergata, Roma, Italy
19 Cleveland Clinic Foundation, Cleveland, Ohio, United States
20 Cleveland Clinic Foundation, Cleveland, Ohio, United States
21 Cleveland Clinic Foundation, Cleveland, Ohio, United States
22 Cleveland Clinic Foundation, Cleveland, Ohio, United States
23 University Hospital San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy
24 Cleveland Clinic Research,, Cleveland, Ohio, United States
25 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Introduction: PNH clone expansion is linked to immune-mediated aplastic anemia, yet the basis of the clonal immune advantage of PNH is not fully clarified. Proposed mechanisms include altered antigen presentation (reported separately), immune-regulatory remodeling, and loss of GPI-anchored proteins (GPI-AP) required for immune responsiveness or serving as immune targets. PIGA loss also alters lipid rafts, and HLA partitions into the same microdomains. We hypothesized that GPI-AP loss thereby reduces antigen presentation in progenitors while remodeling HLA and immune-regulatory ligands in mature cells, altering recognition by cytotoxic T cells.

Methods: Paired GPI-sufficient (GPI+) and GPI-deficient (GPI−) fractions, defined by CD59 loss or FLAER negativity, were profiled in granulocytes, monocytes, and CD45+ leukocytes from 69 PNH/AA-PNH patients and CD34+ progenitors from 13, with healthy whole-blood (n=15) and CD34+ (n=25) controls (HC). HLA-A/B/C, HLA-DP/DQ/DR, B2M, CD47, GITR, VISTA, CD28H, HHLA2, B7-H6, and CD30L were quantified as geometric mean fluorescence, normalized to the paired GPI+ population to reduce interpatient and batch variability, and related to clonal size and targeted myeloid NGS mutations; P values were Benjamini-Hochberg FDR-adjusted. Matched TF1 wild type (WT) and PIGA-deficient cells underwent RNA-seq. Cultures were performed with simvastatin (1 and 5 µM, 60 h); GPI-AP removal was performed using phospholipase C (PI-PLC, 1 U, 30 min to 6 h) in TF1, Jurkat, K562, MOLM13, THP1, and HL60, with CD59/FLAER confirming cleavage.

Results: In TF1, WT HLA-A/B were 1.7 to 1.9 fold and B2M and HLA-DP/DQ/DR 1.5 to 1.8 fold higher than in PIGA-deficient isogenic TF1. RNA-seq confirmed a transcriptional basis: HLA-B fell 5.1 log2, CIITA 5.6, NLRC5 2.5 (both master regulators of HLA expression), TAP1 2.0, and HLA-A, HLA-C, and B2M 0.5 to 1.7 (q<0.01). IFNγ treatment in culture increased but did not completely correct the deficit of HLA expression, which remained below WT TF1 after stimulation despite induction that was at least as strong in this model.

PI-PLC reduced class I across six GPI+ lines; by 3 h HLA-B fell in 6/6 (5% to 29%), HLA-A and HLA-C in 4/6 (8% to 23% and 12% to 33%), with a median CD59 loss of 38%. Simvastatin lowered WT HLA by 10% to 52%: at 1 µM HLA-B 52% and HLA-E 42%; at 5 µM HLA-DR 47%, HLA-DP 43%, B2M 37%, and HLA-A 28%. PIGA-deficient TF1 cells retained the already low HLA expression and were not further affected, consistent with reduced sensitivity to further perturbation.

In CD34+ progenitors, GPI− fell below GPI+ for HLA-A (median log2FC −1.22), HLA-B (−1.03), HLA-C (−0.88), and B2M (−0.84), all q≤0.0018, concordant in 11/13 pairs. Versus HC, GPI+ overexpressed HLA-A (q=0.0096) and HLA-C was comparably high in both fractions (q≤0.048), while GPI− was HLA-DP/DQ-low (q≤0.0019).

Monocytes were directionally comparable to CD34+ cells, with additional loss of immune-regulatory ligands: GPI− fell below GPI+ for GITR (−0.55), CD47 (−0.54), CD30L (−0.50), CD28H (−0.45), B7-H6 (−0.39), HHLA2 (−0.29), VISTA (−0.23), and HLA-A/B/C (−0.19 to −0.09), all q≤0.00016; versus HC both were HLA-A/B-high (q≤0.0069) but GPI− was low for CD47, CD28H, GITR, HLA-C, and VISTA (q≤0.023) and GPI+ HLA-DP-high (q=0.012).

When we correlated clonal size measured in granulocytes with the GPI−/GPI+ B2M ratio by flow cytometry, there was an inverse correlation between clonal size and B2M (rho −0.85), with similar effects observed for HLA-A and HLA-B; flow clone size tracked clinical granulocyte PNH and type III fractions (rho 0.73 to 0.87) and mutation burden (rho 0.62 to 0.66), all q≤0.0086, while individual non-PIGA mutations were underpowered.

Conclusions: One of the factors contributing to immune privilege of PNH cells may be decreased expression of HLA both at the transcriptional level and on the cell surface. The latter effect may be due to disrupted lipid rafts. IFNγ may counteract this effect and we currently investigate whether it can overcome the HLA deficit in patient cells or whether IFNγ signal transduction is also impaired due to impairment of immunologic synapse function in the absence of GPI-anchored proteins, alongside lipid raft and proteostasis responses, compartment-resolved RNA-seq, HLA genotyping, HLA aberration analysis, and mutation profiles.

Kartik Lakhotiya, MS: No relevant conflicts of interest to declare.